Annexin A5 in Patients With Severe COVID-19 Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Feasibility Trial

Annexin A5 in Patients With Severe COVID-19 Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled Feasibility Trial

OBJECTIVES:. To evaluate the study design and feasibility of drug administration and safety in a randomized clinical trial of recombinant human annexin A5 (SY-005), a constitutively expressed protein with anti-inflammatory, antiapoptotic, and anticoagulant properties, in patients with severe coronav...

Full description

Bibliographic Details
Main Authors: Claudio M. Martin, MD, Marat Slessarev, MD, PhD, Eileen Campbell, John Basmaji, MD, Ian Ball, MD, Douglas D. Fraser, MD, PhD, Aleksandra Leligdowicz, MD, PhD, Tina Mele, MD, PhD, Fran Priestap, MSc, Brent J. Tschirhart, MSc, Tracey Bentall, RN, Xiangru Lu, MD, Qingping Feng, MD, PhD
Format: Article
Language:English
Published: Wolters Kluwer 2023-10-01
Series:Critical Care Explorations
Online Access:http://journals.lww.com/10.1097/CCE.0000000000000986

Internet

http://journals.lww.com/10.1097/CCE.0000000000000986

Similar Items